Immunotherapy and Overall Survival Among Patients With Advanced Non-Small Cell Lung Cancer and Obesity. Ihara Y et al.JA…
この記事を読む
一臨床医の勉強のための備忘録です。間違いなどあればご指摘を頂ければ幸いです。
この記事を読む
Immunotherapy and Overall Survival Among Patients With Advanced Non-Small Cell Lung Cancer and Obesity. Ihara Y et al.JA…
この記事を読む
The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Prog…
この記事を読む
Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials. Ve…
この記事を読む
5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC. Velcheti V…
この記事を読む
Randomized Controlled Trial of a Nurse-Led Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Canc…
この記事を読む
Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: A…
この記事を読む
Mechanisms of resistance and correlation between pre-treatment co-alterations and p-prognosis to osimertinib in chemo-na…
この記事を読む
KEYNOTE-671 Investigators. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with …
この記事を読む
Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)treated with osimertinib (osi…
この記事を読む
Neoadjuvant Osimertinib for the Treatment of Stage I-ⅢA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Can…